Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
about
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapyCombined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cellsPhase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines.Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell modelsHistone Deacetylase Inhibitor M344 Inhibits Cell Proliferation and Induces Apoptosis in Human THP-1 Leukemia Cells.Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells.Susceptibility of myelomonocytic leukemia U937 cells to the induction of apoptosis by the non-peptidic Bcl-2 ligand HA14-1 is cell cycle phase-dependent.Histone deacetylase inhibitors: insights into mechanisms of lethality.The potential of proteasome inhibition in the treatment of colon cancer.Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway.Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitorTargeting histone deacetylases for the treatment of diseaseMetastasis-associated gene 1 promotes invasion and migration potential of laryngeal squamous cell carcinoma cells.17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways.Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341.RNA interference of metastasis-associated gene 1 inhibits metastasis of B16F10 melanoma cells in a C57BL/6 mouse model.Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.
P2860
Q24814325-1AAE2F4F-2366-4A44-9A67-57538245C45FQ30409676-7206D908-93CF-41F3-ABCA-8D39ECAB4C6CQ30416647-BB4CDBE0-FADA-4449-A9FF-57D70A1D95F1Q30430515-74EEE97B-BDCC-4F09-9413-4DC4C8C5886DQ30440575-6F4DC82B-21E6-44E7-873F-A61FFE71E246Q33620173-8D3C4EB8-1367-4C02-8214-2F8AF21882D0Q33893161-0F5C5874-4210-4DA9-9A23-17D71EA5E63BQ34158284-C34B1AE7-5DE1-4CED-B77C-3427BDCC235EQ34247883-FA024BBD-437D-4B4E-A636-8A4BB09AE77FQ36219726-A224D058-7703-47CD-AD76-CAC54F4E7034Q36568739-CA81A311-1D28-44B1-9B9C-052D081A65C7Q36705250-ACB3339B-0E7C-48DA-A457-56313ED7CF0BQ37001622-EE49C9C7-489B-40CC-A574-1581910CBBD7Q37296159-5F6D8266-0F9C-447B-9E49-926BD23FE02BQ37437996-DE4D7C5E-8AA3-4086-933A-5DA3D9DE5664Q38915333-FCBF2521-541E-479E-9214-3E2DA6ED246CQ39123831-E2B30710-51A0-471F-B9FD-7852D74641A0Q39587305-BAEF982A-2C12-4005-BD68-A3CB7468505CQ40080615-DBB8577A-D379-4D60-B893-59785A2EEAF5Q40088575-9F00F28E-1F11-4C6B-8E45-D6620DF1772CQ53143241-6D961942-0D9D-4D0D-AA6E-2F85254C960A
P2860
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
@ast
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
@en
type
label
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
@ast
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
@en
prefLabel
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
@ast
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
@en
P2093
P1476
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
@en
P2093
Chadrick E Denlinger
David R Jones
Marty W Mayo
Michael D Keller
R Michael Broad
P304
P356
10.1016/S0022-5223(03)01321-7
P407
P577
2004-04-01T00:00:00Z